SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla secures approval for distribution, marketing of Afrezza Inhalation Powder in India

13 Dec 2024 Evaluate

Cipla has obtained regulatory approval from Central Drugs Standard Control Organisation (CDSCO) for the exclusive distribution and marketing of Afrezza (insulin human) Inhalation Powder in India. Afrezza, a product created and manufactured by MannKind Corporation (MannKind) USA, is used to improve glycemic control in adult patients with diabetes mellitus. By bringing a game-changing, patient-centered solution to diabetes management in India, Cipla will make this drug accessible to all and empower millions to take control of their health with greater ease.

Afrezza is a rapid-acting insulin delivered through an inhaler as compared to current insulins which are given as injections. Taken at the beginning of a meal, Afrezza dissolves rapidly upon oral inhalation into the lungs and delivers insulin quickly to the bloodstream. Afrezza starts working in as early as 12 minutes and helps in reducing the rapid increase seen in sugar levels with meals. The effect of Afrezza lasts for about 2-3 hours and it closely resembles the body’s own response to insulin. This is the first and only noninjectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.


Cipla Share Price

1304.90 -0.95 (-0.07%)
24-Apr-2026 09:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1674.60
Dr. Reddys Lab 1291.00
Cipla 1304.90
Zydus Lifesciences 947.50
Lupin 2357.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×